Evidence map›Paper›PMID 42350041›Full record

ArticleJournal for immunotherapy of cancer2026

Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39

Jiajuan Wu, Jiawei Zhai, Leilei Lv, Yaoxin Zhang, Yu Shen, Qiuxia Qu, Cheng Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiajuan Wu *Clinical Immunology Institute, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0009-0008-3114-0272
Jiawei Zhai *Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0000-0003-2080-1641
Leilei Lv *Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0009-0008-9615-1706
Yaoxin ZhangDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0000-0001-5540-4959
Yu ShenClinical Immunology Institute, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID http://orcid.org/0000-0002-7573-8996
Qiuxia QuClinical Immunology Institute, The First Affiliated Hospital of Soochow University, Suzhou, China chencheng@suda.edu.cn qxqu@suda.edu.cn.ORCID http://orcid.org/0000-0002-2836-2092
Cheng ChenDepartment of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, China chencheng@suda.edu.cn qxqu@suda.edu.cn.ORCID http://orcid.org/0000-0002-9583-7991

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnderstanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39)

methodsWe employed targeted biopsy techniques to characterize the spatial infiltration of CD39

resultsRegion-specific CD39

conclusionsThese findings identify CD39

Indexed as

ApyraseCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesDrug Resistance, NeoplasmImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsProgrammed Cell Death 1 ReceptorAnimalsAntigens, CDFemaleHumansMiceTumor MicroenvironmentAntigens, CDApyraseCD39 antigenENTPD1 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorImmunotherapyLung CancerT cellTumor microenvironment - TME

Identifiers

PMID42350041
PMCPMC13311774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.